Citations

Showing 10 of 108119 citations.

Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.
Infante, Jeffrey R., Burris, Howard A. , Ansell, Stephen M. , Villalobos, Víctor M. , Šikić, Branimir I. , Northfelt, Donald W. , Pilja, Lana, Hawthorne, Thomas, Davis, Thomas A. , Keler, Tibor , Nemunaitis, John , Weiss, Geoffrey R. , Taylor, Matthew H. , Carson, William E. , Yellin, Michael , Bullock, Timothy N J

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3027-3027

10.1200/jco.2014.32.15_suppl.3027 Get It

Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.
Ansell, Stephen M. , Northfelt, Donald W. , Burris, Howard A. , Dinner, Shira, Villalobos, Víctor M. , Šikić, Branimir I. , Pilja, Lana, Hawthorne, Thomas, Keler, Tibor , Davis, Thomas A., Flinn, Ian W. , Taylor, Matthew H. , Yellin, Michael , Davis, Thomas A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3024-3024

10.1200/jco.2014.32.15_suppl.3024 Get It

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Kefford, Richard , Hamid, Omid , Hodi, F. Stephen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Dolled‐Filhart, Marisa, Lunceford, Jared , Emancipator, Kenneth , Ebbinghaus, Scot, Kang, Soonmo Peter, Hwu, Wen‐Jen , Ribas, Antoni , Robert, Caroline , Daud, Adil , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3005-3005

10.1200/jco.2014.32.15_suppl.3005 Get It

A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.
Ahern, Charlotte H., Kudgus, Rachel A. , Fox, Elizabeth , Blaney, Susan M. , Weigel, Brenda J. , Geller, James I. , Perentesis, John P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2627-2627

10.1200/jco.2014.32.15_suppl.2627 Get It

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.
Renshaw, Frank Gary, Genvresse, Isabelle , Reif, Stefanie , Kaplan, Jennifer A. , Kim, Richard D. , Alberts, Steven R. , Kaplan, Jennifer, Grilley‐Olson, Juneko E.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2610-2610

10.1200/jco.2014.32.15_suppl.2610 Get It

Aurora-A mitotic kinase and induction of endocrine resistance through downregulation of erα expression in initially erα+ breast cancer cells.
Salisbury, Jeffrey L., Zhang, Shuya , Hawse, John R. , Haddad, Tufia C. , D’Assoro, Antonino B. , Opyrchal, Mateusz , McCubrey, James Andrew , Goetz, Matthew P. , Degnim, Amy C. , Lange, Carol Ann , Ingle, James N. , Galanis, Evanthia

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2568-2568

10.1200/jco.2014.32.15_suppl.2568 Get It

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Kim, George P., Qin, Rui , Lensing, Janet L., Wright, John Joseph, Erlichman, Charles , Grothey, Axel, Hubbard, Joleen M. , Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2539-2539

10.1200/jco.2014.32.15_suppl.2539 Get It

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
Hurwitz, Herbert I. , Pitot, Henry C., Smith, David C. , Brill, Jeffrey Mark, Vuagniaux, Grégoire, Rouits, Elisabeth , Zanna, Claudio , Sorensen, John M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2532-2532

10.1200/jco.2014.32.15_suppl.2532 Get It

A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Yue, Huibin, Scales, Suzie J. , Samineni, Divya , Wood, Katie, Brunstein, Flávia, Maslyar, Daniel, Kim, George P., Borad, Mitesh J. , McWilliams, Robert R. , Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Lieu, Christopher H. , Wang, Yulei

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2529-2529

10.1200/jco.2014.32.15_suppl.2529 Get It

A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel.
John, Kovach, Chung, Vincent , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS2636-TPS2636

10.1200/jco.2014.32.15_suppl.tps2636 Get It